Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more
Apellis Pharmaceuticals Inc (APLS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.038x
Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has a cash flow conversion efficiency ratio of -0.038x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.18 Million) by net assets ($370.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apellis Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Apellis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Feilong Auto Components Co Ltd
SHE:002536
|
0.026x |
|
Recordati Industria Chimica e Farmaceutica S.p.A.
PINK:RICFY
|
0.079x |
|
CES ENERGY SOLUTIONS
F:7C4
|
N/A |
|
Mitie Group plc
PINK:MITFF
|
0.175x |
|
Pilgrims Pride Corp
NASDAQ:PPC
|
0.079x |
|
Tibet Mineral Development Co Ltd
SHE:000762
|
0.009x |
|
HAZAMA ANDO CORP.
F:2PW
|
N/A |
|
Shaanxi Sirui Advanced Materials Co. Ltd. A
SHG:688102
|
N/A |
Annual Cash Flow Conversion Efficiency for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Apellis Pharmaceuticals Inc from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $370.15 Million | $45.33 Million | 0.122x | +131.85% |
| 2024-12-31 | $228.54 Million | $-87.87 Million | -0.384x | +87.43% |
| 2023-12-31 | $194.52 Million | $-594.74 Million | -3.057x | -1.10% |
| 2022-12-31 | $169.87 Million | $-513.75 Million | -3.024x | -6.69% |
| 2021-12-31 | $198.66 Million | $-563.13 Million | -2.835x | -261.30% |
| 2020-12-31 | $204.56 Million | $-160.49 Million | -0.785x | +87.28% |
| 2019-12-31 | $34.23 Million | $-211.13 Million | -6.168x | -656.56% |
| 2018-12-31 | $160.97 Million | $-131.24 Million | -0.815x | -160.61% |
| 2017-12-31 | $148.94 Million | $-46.60 Million | -0.313x | +71.37% |
| 2016-12-31 | $23.79 Million | $-26.00 Million | -1.093x | -102.71% |
| 2015-12-31 | $34.98 Million | $-18.86 Million | -0.539x | +28.33% |
| 2014-12-31 | $13.22 Million | $-9.95 Million | -0.752x | +1.25% |
| 2013-12-31 | $4.52 Million | $-3.44 Million | -0.762x | -- |